Quotables
"I hate what they've done to my child...I would never let my own children watch it. "
Vladimir Zworykin, television pioneer ; Talking about an invention in which he played a critical role.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173675 | Substituted amino-thiourea compounds for combating animal pests The invention relates to substituted amino-thiourea compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted amino-thiourea compounds, of the... | 05/08/2012 |
| 8168656 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of o... | 05/01/2012 |
| 8124622 | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by conta... | 02/28/2012 |
| 8114892 | Methods and compositions for the treatment of Parkinson's Disease The invention features methods and kits for treating or inhibiting the development of Parkinson's Disease by administering 7-chloro-4-aminoquinoline compounds, e.g., amodiaquine or glafenine. Stem cells are also useful in the methods of the invention and may be admi... | 02/14/2012 |
| 8106071 | Compositions for treating hyperproliferative vascular disorders and cancers The present invention relates to a method for treating or reducing the development of a hyperproliferative disorder, which comprises administering to a subject a composition, which comprises as an active ingredient the compound rep... | 01/31/2012 |
| 8063066 | MAPK/ERK kinase inhibitors Compounds are provided for use with MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and inte... | 11/22/2011 |
| 8063067 | Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes f... | 11/22/2011 |
| 8053445 | Utilities of olefin derivatives Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic het... | 11/08/2011 |
| 8048894 | Quinolones and azaquinolones that inhibit prolyl hydroxylase Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein. ... | 11/01/2011 |
| 8022086 | Therapeutic agent for glomerular disease The present invention relates to a preventive and/or therapeutic agent for a glomerular disease containing, as active ingredients, pitavastatin or a salt thereof and candesartan cilexetil or a salt thereof. The agent of the present invention exhibits an excellent ef... | 09/20/2011 |
| 7989472 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. ... | 08/02/2011 |
| 7977354 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents The invention is related to compound which comprises at least one radical C═Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C═Y and the nitrogen atom, when o... | 07/12/2011 |
| 7973053 | Nerve cell death inhibitor The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action. The present invention relates to a nerve cell death inhibitor comprising a pitavastatin and donepezil or a salt thereof in combination. ... | 07/05/2011 |
| 7968567 | Compounds for the modulation of PPARγ activity Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity. ... | 06/28/2011 |
| 7964614 | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likeli... | 06/21/2011 |
| 7960408 | Quinolinyl and benzothiazolyl modulators Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful ... | 06/14/2011 |
| 7947711 | Bicyclic-substituted amines as histamine-3 receptor ligands Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands... | 05/24/2011 |
| 7935713 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. ... | 05/03/2011 |
| 7897619 | Heterocyclic modulators of PKB The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention als... | 03/01/2011 |
| 7868020 | Quinolynylmethylimidizoles as therapeutic agents Disclosed herein is a compound of the formula (I):(I). Therapeutic methods, compositions and medicaments related thereto are also disclosed. ... | 01/11/2011 |
| 7863293 | CXCR4 chemokine receptor binding compounds The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates t... | 01/04/2011 |
| 7858640 | Quinolines and their therapeutic use Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory components; in which: R1-R9 are various substituents; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10 | 12/28/2010 |
| 7851486 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for ... | 12/14/2010 |
| 7807693 | Substituted prolinamides, manufacturing, and the use thereof as medicaments The present invention relates to new substituted prolinamides of general formula (I) wherein D, L, E, G, J, M, R3, R4, R5 and R13 are defined as in the specification, the tautomer... | 10/05/2010 |
| 7786139 | PDE10 inhibitors and related compositions and methods Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer... | 08/31/2010 |
| 7786138 | Process for making montelukast and intermediates therefor A compound of the following formula wherein R′ is a straight or branched C1-C4 alkyl group is useful in processes associated with the synthesis of montelukast and its salts. ... | 08/31/2010 |
| 7776881 | Hyperlipemia therapeutic agent A hypertriglyceridemia therapeutic agent made up of a synergistically effective blood-triglyceride decreasing amount of a combination of a pitavastatin and eicosapentaenoic acid (EPA), or an ester thereof. ... | 08/17/2010 |
| 7696225 | (2-carboxamido)(3-Amino) thiophene compounds Amidoaryl/amidoheteroaryl substituted thiophenes, further substituted with a heteroarylmethylamino group, are useful in the treatment of cancer. ... | 04/13/2010 |
| 7655674 | Modulators of hedgehog signaling pathways, compositions and uses related thereto The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small ... | 02/02/2010 |
| 7652036 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalin... | 01/26/2010 |
| 7652037 | Methods of lowering lipid levels in a mammal This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced l... | 01/26/2010 |
| 7645773 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositi... | 01/12/2010 |
| 7632845 | Phenyl quinolines and their use as estrogenic agents This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, R3, R4, R5, and R6 are as defined in th... | 12/15/2009 |
| 7632846 | Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes f... | 12/15/2009 |
| 7601741 | Process for making montelukast and intermediates therefor The reaction of methylmagnesium halide is improved by the presence of a cerium (III) salt such as cerium trichloride. The reactions are typically associated with the production of montelukast, a pharmaceutically useful compound of the following formula | 10/13/2009 |
| 7595328 | Methods of use of quinolone compounds against pneumococcal and bacteria This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pneumoniae and rare H. influenzae strains. ... | 09/29/2009 |
| 7592356 | Triazoles as farnesyl transferase inhibitors a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independent... | 09/22/2009 |
| 7576099 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals ... | 08/18/2009 |
| 7563804 | FMF treatment The method of improving FMF control, in humans, which includes administering, on an average daily basis, between 5 and 15 milligrams of LTRA to a patient suffering from FMF. ... | 07/21/2009 |
| 7553853 | Solid-state montelukast A solid form of a compound of formula 1: is provided. The compound of formula 1 can be obtained in solid state by precipitation from a solution containing the same. The compound is useful as leukotriene antagonist and can b... | 06/30/2009 |
